A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab

Keima Ito; Tetsuya Oguri; Norihisa Takeda; Kensuke Fukumitsu; Satoshi Fukuda; Yoshihiro Kanemitsu; Tomoko Tajiri; Hirotsugu Ohkubo; Masaya Takemura; Ken Maeno; Yutaka Ito; Akio Niimi

doi:10.1016/j.rmcr.2019.100979

A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab

Respir Med Case Rep. 2019 Dec 10:29:100979. doi: 10.1016/j.rmcr.2019.100979. eCollection 2020.

Authors

Affiliations

¹ Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
² Department of Education and Research Center for Community Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Abstract

A 76-year-old man was admitted to our hospital with cough and dyspnea. He was diagnosed with advanced lung cancer. Nivolumab was given as second-line treatment, cytotoxic chemotherapy was given as third-line treatment, and nivolumab re-challenge was given as fourth-line treatment. Thereafter, 41 chemotherapy courses were administered over 2 years. Currently, he is being followed with no recurrence at least 10 months after treatment. Thus, the case of a patient with advanced lung cancer who was previously unsuccessfully treated with nivolumab and then demonstrated a long-term clinical response to a re-challenge with nivolumab after cytotoxic chemotherapy and radiation therapy is presented.

Keywords: Immune checkpoint inhibitors; Lung cancer; Nivolumab; PD-L1.

Publication types

Case Reports